Clinical Trial Update: A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating HHPG-19K Injection and Auto-HHPG-19K Injection to prevent chemotherapy-related neutropenia in patients with nonmyeloid malignancies h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonmyeloid Malignancies

Drugs mentioned

• Auto-HHPG-19K Injection
• HHPG-19K Injection

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk | Phase 3 | Status: WITHDRAWN